𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I/II trial of weekly cisplatin, etoposide, and irinotecan chemotherapy for metastatic lung cancer: JCOG 9507

✍ Scribed by Sekine, I; Nishiwaki, Y; Kakinuma, R; Kubota, K; Hojo, F; Matsumoto, T; Ohmatsu, H; Goto, K; Kodama, T; Eguchi, K

Book ID
109997502
Publisher
Nature Publishing Group
Year
2003
Tongue
English
Weight
109 KB
Volume
88
Category
Article
ISSN
0007-0920

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of irinotecan, cisplatin
Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer
✍ Dean A. Fennell; Jeremy P.C. Steele; Jonathan Shamash; Sarah E. Slater; Michael πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 French βš– 87 KB πŸ‘ 1 views

## Abstract There is no standard therapy for relapsed small cell lung cancer (rSCLC). We evaluated the efficacy and toxicity of a new triplet consisting of irinotecan (100 mg/m^2^ Days 1 and 15 q28), cisplatin (40 mg/m^2^ Days 1 and 15 q28) and mitomycin (6 mg/m^2^ d1 q28) administered to a maximum

Phase I/II study of a combined gemcitabi
Phase I/II study of a combined gemcitabine, etoposide, and cisplatin chemotherapy regimen for metastatic urothelial carcinoma
✍ Tetsuro Tsukamoto; Junji Yonese; Yuhei Ohkubo; Iwao Fukui πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 112 KB

## Abstract ## BACKGROUND The authors attempted to determine the maximum tolerated dose (MTD) of gemcitabine in combination with etoposide and cisplatin as a chemotherapy regimen and investigated the safety and antitumor activity with the recommended doses of gemcitabine with etoposide and cisplat